Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCENT: Analgesic and Appetite-stimulating Effects of CBG and THC
NCT04859296Phase 1Active, not recruiting
- Sponsor
- University of California, Los Angeles
- Start
- Feb 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cannabigerol in pain and anorexia nervosa (AN) (9 arms), sponsored by University of California, Los Angeles. Primary endpoints: Analgesia at 7 hours, Appetite stimulation at 7 hours and 1 more. Started Feb 2023; status: active, not recruiting.
02
Drugs
cannabigerol
03
Conditions
painanorexia nervosa (AN)
Beyond the preview
Go deeper on NCT04859296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04859296.